BPC-157 vs TB-500: What’s the Difference?
BPC-157 and TB-500 are different molecules with different parent proteins. BPC-157 is a 15-amino-acid synthetic peptide based on a sequence from a protective protein found in gastric juice; TB-500 is a synthetic peptide based on thymosin beta-4, an actin-binding protein involved in cell migration. They are not interchangeable, and the differences — origin, structure and the mechanisms the literature actually studies — are the subject of this guide. Both are sold here strictly for laboratory research.
BPC-157 vs TB-500 at a glance
| BPC-157 | TB-500 | |
|---|---|---|
| Parent protein / origin | Partial sequence of Body Protection Compound, a protein in gastric juice | Thymosin beta-4 (Tβ4), an actin-binding protein present in most cells |
| Length / type | 15 amino acids, synthetic | Synthetic Tβ4-based peptide (see naming note below) |
| Approx. molecular weight | ~1,419 Da | Depends on the form supplied — the batch COA states the exact sequence and mass |
| Mechanisms studied | Localised growth-factor signalling: angiogenesis, VEGFR2 and nitric-oxide pathway studies | G-actin sequestration and actin regulation; cell-migration assays |
| Typical research models | Tendon-fibroblast cultures, rodent GI and soft-tissue models | Cell-migration assays, rodent wound and cardiac-injury models |
| Form supplied | 10mg lyophilized vial | 10mg lyophilized vial |
| Purity spec / COA | ≥99% HPLC — batch COA | ≥99% HPLC — batch COA |
Naming note: “TB-500” is used inconsistently across the market — some vendors mean full-length thymosin beta-4 (43 amino acids), others the short active fragment around the actin-binding region. The only reliable answer is the certificate: our batch COA states the exact sequence and mass tested for the vial you receive.
What BPC-157 is studied for
BPC-157’s literature is concentrated in localised tissue models. The most-cited threads are angiogenesis work — including studies of VEGFR2 signalling and the nitric-oxide pathway — alongside tendon-fibroblast culture experiments and a long run of rodent gastrointestinal and soft-tissue studies. The common shape across this work: a locally acting peptide investigated for how damaged tissue environments respond, in vitro and in animal models.
Those findings describe laboratory models, not this research material, and no human outcome is implied. Specifications and the current certificate are on the BPC-157 product page; the research record in more depth is in the BPC-157 research guide and the library entry.
What TB-500 (thymosin beta-4) is studied for
TB-500 is a synthetic peptide based on thymosin beta-4, a small actin-binding protein found in nearly all cells. Its defining studied mechanism is G-actin sequestration — regulating the building blocks of the cellular skeleton — which is why its literature is dominated by cell-migration assays, plus rodent wound models and cardiac-injury models. Where BPC-157’s work is largely about local tissue environments, Tβ4’s is about how cells move. Specifications: the TB-500 product page and library entry.
The core differences, explained
Origin and structure
Unrelated sequences from unrelated parent proteins: a gastric-protein fragment (BPC-157) versus an actin-binding cellular protein (Tβ4). Neither is a version, fragment or analog of the other.
Mechanisms studied
BPC-157’s literature centres on localised growth-factor and nitric-oxide signalling; TB-500’s centres on actin regulation and cell migration. Different pathways, which is why research designs treat them as complementary rather than interchangeable.
Research-model emphasis
BPC-157 appears most in tendon, ligament and GI models; TB-500 in migration assays and systemic wound models. A study design usually points clearly at one or the other.
Handling and stability
Identical logistics: both ship as lyophilized powder, stable cold and dark, and are reconstituted with bacteriostatic water for laboratory use. See how to reconstitute and store peptides and how long reconstituted peptides last.
Is BPC-157 the same as TB-500?
No. They are unrelated sequences from different parent proteins, with different studied mechanisms. They get confused because they are sold and studied side by side in the same corner of the research literature — not because they are variants of one molecule.
Why they’re often studied together
Their studied mechanisms barely overlap — localised growth-factor signalling on one side, actin-driven cell migration on the other — and that complementarity is exactly why paired designs appear in the repair literature. The pairing has its own guide: the BPC-157 + TB-500 stack in research. For the wider category, see healing & recovery research peptides in Canada.
Single compounds vs the combined vial
Quantum supplies both routes: separate BPC-157 and TB-500 vials (10mg each), or the pre-combined Wolverine blend — one 20mg vial containing 10mg of each, with its own batch COA. Which format suits a study is a design question; the compounds are the same either way.
Choosing between them for a research model
Frame the choice by the research question. Work on localised growth-factor signalling, angiogenesis or GI/tendon tissue models points to BPC-157. Work on actin regulation, cell migration or systemic wound models points to TB-500. Whichever fits, verify the batch before it enters a protocol-free lab workflow: every Quantum batch is independently tested to a ≥99% HPLC purity target with mass-spec identity confirmation.
Verifying what you receive
Both compounds carry batch-matched certificates from an independent Canadian laboratory: BPC-157 COA, TB-500 COA and Wolverine blend COA. The certificate shows HPLC purity and mass-spec identity for the exact batch number printed on the vial — here is how to read one. A TB-500 certificate also settles the naming question above, because it states the precise sequence tested.
See also: BPC-157 vs GHK-Cu, the sibling comparison.
Frequently asked questions
What is the difference between BPC-157 and TB-500?
Different parent proteins and different studied mechanisms: BPC-157 is a 15-amino-acid gastric-protein fragment studied in localised growth-factor and tissue models, while TB-500 is based on thymosin beta-4 and studied for actin regulation and cell migration.
Is BPC-157 the same as TB-500?
No — they are distinct sequences from unrelated parent proteins. They are often mentioned together because they sit side by side in the repair-research literature, not because one is a form of the other.
Which is better, BPC-157 or TB-500?
Neither is “better”. They are studied in different research models, and the right compound depends on the research question — the comparison table above maps which literature each one belongs to.
Are BPC-157 and TB-500 studied together?
Yes, paired designs appear in the literature because the mechanisms are complementary. Quantum supplies them separately or pre-combined as the Wolverine blend; the pairing has its own stack guide.
What does “TB-500” refer to: thymosin beta-4 or a fragment?
Both usages exist in the market, which is why the label alone is not enough. Our batch COA states the exact sequence and mass tested for the vial supplied.
Are your BPC-157 and TB-500 third-party tested?
Yes — every batch is tested by an independent Canadian laboratory with HPLC purity and mass-spec identity confirmation, and the batch-matched certificates are published on the lab results hub. Ships from Canadian stock.
Can you provide dosing information?
No. We supply research materials only and do not provide dosing, administration or human-use guidance of any kind.
All products are sold strictly for laboratory and research use only. Not for human consumption. This page describes what is studied in the published literature and makes no claims about effects in people.